Pricing Log in Create free account

SCYNEXIS, Inc. (SCYX) vs TherapeuticsMD, Inc. (TXMD)

SCYNEXIS, Inc. and TherapeuticsMD, Inc. are both Drug Manufacturers Specialty & Generic companies. SCYNEXIS, Inc. is the larger, with a market value of $34.8M against $20.1M — 1.7× the size. SCYNEXIS, Inc. grew revenue faster over the last twelve months: 682.5% against 27.8%. TherapeuticsMD, Inc. has the higher net margin (−6.64% vs −49.7%) and the higher return on invested capital (−13.8% vs −110.7%). Across the 16 metrics below, TherapeuticsMD, Inc. leads on 9 and SCYNEXIS, Inc. on 7.

Valuation

Metric SCYX TXMD Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.45
P/S 2.01 6.16 2.11
P/B 0.62 0.74 1.69
Price to free cash flow n/m 7.40 15.98
EV/EBITDA n/m n/m 12.21
EV/Sales 0.64 84.49 2.79
Earnings yield (59.71%) (1.34%) (15.61%)
Free cash flow yield (32.20%) 13.51% 0.00%

Profitability

Metric SCYX TXMD Drug Manufacturers Specialty & Generic median
Gross margin 100.00% 100.00% 53.51%
Operating margin (109.90%) (120.89%) 0.00%
Net margin (49.74%) (6.64%) (2.31%)
Free cash flow margin (64.67%) 94.71% 0.00%
Return on equity (18.38%) (0.80%) (0.80%)
Return on assets (15.09%) (0.57%) (1.67%)
Return on invested capital (110.72%) (13.77%) 0.00%

Growth

Metric SCYX TXMD Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 682.47% 27.78% 5.22%
EPS growth (last fiscal year) 61.36% 73.68% 42.91%
Revenue growth, 5-year CAGR 179.40% (45.84%) 7.24%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric SCYX TXMD Drug Manufacturers Specialty & Generic median
Debt to equity 0.00 0.00 0.04
Current ratio 9.65 3.22 2.46
Net debt to EBITDA 2.54 2.34 1.01

Dividend

Metric SCYX TXMD Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.47%
Payout ratio — — 0.28

Size

Metric SCYX TXMD Drug Manufacturers Specialty & Generic median
Market cap 34.84m 20.14m 300.78m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack